Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032

1
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Molecular
Oncology
Diagnostics
Market -
A Global and
Regional Analysis
Focus on Product, Technology,
Application, Cancer Type, End User, and
Region
Analysis and Forecast: 2022-2032
November 2022
Table of Content

2
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Table of Content
Executive Summary..........................................................................24
1. Market .......................................................................................32
1.1 Product Definition............................................................................................33
1.2 Inclusion and Exclusion..................................................................................34
1.3 Scope of the Study ..........................................................................................34
1.4 Key Questions Answered in the Report.........................................................35
2. Research Methodology ..............................................................37
2.1 Global Molecular Oncology Diagnostics Market: Research
Methodology ....................................................................................................37
2.2 Primary Data Sources .....................................................................................37
2.3 Secondary Data Sources ................................................................................38
2.4 Market Estimation Model.................................................................................39
2.5 Criteria for Company Profiling........................................................................41
3. Global Molecular Oncology Diagnostics Market: Overview.........42
3.1 Market Overview ..............................................................................................42
3.1.1 Evolution of Molecular Cancer Diagnostics and Current Status..................... 42
3.2 Global Molecular Oncology Diagnostics Market Size and Forecast
(2021-2032) .......................................................................................................43
3.3 Global Incidence and Prevalence of Cancer (by Type) ................................44
3.3.1 North America ...................................................................................................... 44
3.3.1.1 Solid Tumor .................................................................................................... 44
3.3.1.2 Hematological Malignancy.............................................................................. 45
3.3.2 Europe................................................................................................................... 46
3.3.2.1 Solid Tumor .................................................................................................... 46
3.3.3 Asia-Pacific........................................................................................................... 48
3.3.3.1 Solid Tumor .................................................................................................... 48
3.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market.........49

4
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
3.4.1 Impact on Market Size ......................................................................................... 50
3.5 Liquid Biopsy-Based Cancer Molecular Diagnostics ...................................51
3.6 Laboratory Developed Test (LDT) Vs. In Vitro Diagnostic (IVD)..................52
3.7 Role of Companion Diagnostics in the Molecular Oncology
Diagnostics Market..........................................................................................52
4. Global Molecular Oncology Diagnostics Market: Industry
Analysis.....................................................................................55
4.1 Legal Requirements and Framework in the U.S............................................56
4.1.1 FDA Regulation .................................................................................................... 56
4.1.2 CMS Regulation (Reimbursement Scenario)..................................................... 57
4.2 Legal Requirements and Framework in Europe............................................58
4.3 Legal Requirements and Framework in Asia-Pacific....................................59
4.3.1 China ..................................................................................................................... 59
4.3.2 Japan..................................................................................................................... 60
5. Market Dynamics .......................................................................62
5.1 Overview...........................................................................................................63
5.1 Impact Analysis ...............................................................................................63
5.2 Growth Drivers.................................................................................................65
5.2.1 Rising Incidence of Cancer Cases ..................................................................... 65
5.2.2 Launch of Innovative Products in Molecular Oncology Diagnostics
Ecosystem ............................................................................................................ 67
5.2.3 Growth in Biomarker identification and Transformations in Molecular
Techniques ........................................................................................................... 67
5.3 Growth Restraints............................................................................................69
5.3.1 Lack of Qualified Professionals.......................................................................... 69
5.3.2 Opaque Regulatory Framework Delaying the Approval of New Molecular
Diagnostic Tests .................................................................................................. 69
5.3.3 High Cost of Equipment Hindering the Adoption Rate..................................... 70
5.4 Growth Opportunities......................................................................................71
5.4.1 Partnerships and Collaborations between Various Healthcare
Stakeholders......................................................................................................... 71

5
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
5.4.2 Upsurge of Next-Generation Ultrasensitive Molecular Diagnostics................ 72
6. Competitive Landscape .............................................................74
6.1 Mergers and Acquisitions...............................................................................76
6.2 Synergistic Activities ......................................................................................77
6.3 Product Launch and Approval Activities.......................................................78
6.4 Expansion, Insurance, and Other Key Developments..................................79
6.5 Market-Share Analysis ....................................................................................79
6.6 Growth-Share Analysis ...................................................................................81
7. Global Molecular Oncology Diagnostics Market (by Product),
$Million, 2021-2032....................................................................83
7.1 Overview...........................................................................................................84
7.2 Kits and Assays...............................................................................................85
7.3 Instruments ......................................................................................................87
7.4 Software ...........................................................................................................88
8. Global Molecular Oncology Diagnostics Market (by
Technology), $Million, 2021-2032...............................................90
8.1 Overview...........................................................................................................91
8.2 Polymerase Chain Reaction (PCR).................................................................93
8.3 Next-Generation Sequencing (NGS) ..............................................................94
8.4 Immunohistochemistry (IHC)..........................................................................95
8.5 Fluorescence In-Situ Hybridization (FISH) ....................................................96
8.6 Flow Cytometry................................................................................................97
8.7 Other Technologies.........................................................................................98
9. Global Molecular Oncology Diagnostics Market (by
Application), $Million, 2021-2032 ...............................................99
9.1 Overview.........................................................................................................100
9.2 Clinical Diagnostic.........................................................................................101
9.3 Research Use.................................................................................................102
10. Global Molecular Oncology Diagnostics Market (by Cancer
Type), $Million, 2021-2032 .......................................................103
10.1 Overview.........................................................................................................104

6
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
10.1.1 Solid Tumor ........................................................................................................ 105
10.1.1.1 Breast Cancer............................................................................................... 106
10.1.1.2 Lung Cancer ................................................................................................. 107
10.1.1.3 Colorectal Cancer ......................................................................................... 108
10.1.1.4 Prostate Cancer............................................................................................ 109
10.1.1.5 Ovarian Cancer............................................................................................. 110
10.1.1.6 Other Solid Tumors....................................................................................... 111
10.1.2 Hematological Malignancy ................................................................................ 112
10.1.2.1 Lymphoma.................................................................................................... 113
10.1.2.2 Leukemia ...................................................................................................... 114
10.1.2.3 Multiple Myeloma.......................................................................................... 115
10.1.2.4 Other Hematological Malignancies ............................................................... 116
11. Global Molecular Oncology Diagnostics Market (by End User),
$Million, 2021-2032..................................................................118
11.1 Overview.........................................................................................................119
11.2 Hospitals and Diagnostic Centers................................................................120
11.3 Reference Laboratories.................................................................................121
11.4 Pharmaceutical and Biotechnology Companies.........................................122
11.5 Academic and Research Institutes ......................Error! Bookmark not defined.
12. Region .....................................................................................124
12.1 Overview.........................................................................................................125
12.2 North America................................................................................................127
12.2.1 U.S. ...................................................................................................................... 131
12.2.2 Canada ................................................................................................................ 134
12.3 Europe ............................................................................................................138
12.3.1 Germany.............................................................................................................. 141
12.3.2 France ................................................................................................................. 145
12.3.3 U.K....................................................................................................................... 149
12.3.4 Italy...................................................................................................................... 152
12.3.5 Spain ................................................................................................................... 155

7
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
12.3.6 Rest-of-Europe ................................................................................................... 159
12.4 Asia-Pacific ....................................................................................................162
12.4.1 China ................................................................................................................... 165
12.4.2 India..................................................................................................................... 169
12.4.3 Japan................................................................................................................... 172
12.4.4 South Korea........................................................................................................ 176
12.4.5 Australia.............................................................................................................. 179
12.4.6 Rest-of-Asia-Pacific ........................................................................................... 183
12.5 Rest-of-the-World (RoW)...............................................................................187
13. Company Profiles.....................................................................189
13.1 Agilent Technologies, Inc. ............................................................................191
13.1.1 Company Overview............................................................................................ 191
13.1.2 Role of Agilent Technologies, Inc. in the Global Molecular Oncology
Diagnostics Market ............................................................................................ 191
13.1.3 Key Competitors of the Company .................................................................... 191
13.1.4 Business Strategies........................................................................................... 192
13.1.4.1 Merger and Acquisition ................................................................................. 192
13.1.4.2 Product Launch/Approval ............................................................................. 192
13.1.4.3 Expansion..................................................................................................... 192
13.1.5 Financials............................................................................................................ 193
13.1.6 Analyst Perspective........................................................................................... 195
13.2 Abbott. ............................................................................................................196
13.2.2 Role of Abbott. in the Global Molecular Oncology Diagnostics Market ....... 196
13.2.4 Key Customers of the Company....................................................................... 197
13.2.5 Financials............................................................................................................ 197
13.2.6 Key Insights about the Financial Health of the Company.............................. 199
13.3 Biocartis NV ...................................................................................................201

8
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
13.3.2 Role of Biocartis NV in the Global Molecular Oncology Diagnostics
Market.................................................................................................................. 201
13.3.4 Corporate Strategies.......................................................................................... 201
13.3.4.1 Synergistic Activities ..................................................................................... 201
13.3.6 Financials............................................................................................................ 203
13.4 Bio-Rad Laboratories, Inc. ............................................................................204
13.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Molecular Oncology
13.4.6 Financials............................................................................................................ 206
13.5 F. Hoffmann-La Roche Ltd............................................................................209
13.5.2 Role of F. Hoffmann-La Roche Ltd. in the Global Molecular Oncology

9
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
13.5.5.2 Expansion..................................................................................................... 210
13.5.6 Financials............................................................................................................ 211
13.6 QIAGEN N.V....................................................................................................215
13.6.2 Role of QIAGEN N.V. in the Global Molecular Oncology Diagnostics
Market.................................................................................................................. 215
13.6.7 Financials............................................................................................................ 217
13.7 Thermo Fisher Scientific, Inc........................................................................221
13.7.2 Role of Thermo Fisher Scientific, Inc. in the Global Molecular Oncology
13.7.5.2 Expansion..................................................................................................... 222
13.7.6 Financials............................................................................................................ 223
13.8 Danaher. .........................................................................................................227

10
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
13.8.2 Role of Danaher. in the Global Molecular Oncology Diagnostics Market..... 227
13.8.5 Financials............................................................................................................ 229
13.9 Guardant Health.............................................................................................232
13.9.2 Role of Guardant Health in the Global Molecular Oncology Diagnostics
Market.................................................................................................................. 232
13.9.7 Financials............................................................................................................ 234
13.10 HTG Molecular Diagnostics, Inc...................................................................238
13.10.2 Role of HTG Molecular Diagnostics, Inc. in the Global Molecular
Oncology Diagnostics Market........................................................................... 238
13.10.5 Financials............................................................................................................ 240

11
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
13.11 Illumina, Inc....................................................................................................243
13.11.2 Role of Illumina, Inc. in the Global Molecular Oncology Diagnostics
Market.................................................................................................................. 243
13.11.6 Financials............................................................................................................ 245
13.12 Invivoscribe, Inc.............................................................................................249
13.12.2 Role of Invivoscribe, Inc. in the Global Molecular Oncology Diagnostics
Market.................................................................................................................. 249
13.13 Myriad Genetics, Inc......................................................................................252
13.13.2 Role of Myriad Genetics, Inc. in the Global Molecular Oncology

12
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
13.13.6 Financials............................................................................................................ 254
13.14 Sysmex Corporation......................................................................................257
13.14.2 Role of Sysmex Corporation in the Global Molecular Oncology
13.14.5.2 Expansion..................................................................................................... 258
13.14.6 Financials............................................................................................................ 259

13
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
List of Figures
Figure 1: Annual NIH Funding in Human Genomics Research, $Billion, FY2013-FY2019
Figure 2: Global Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 3: Global Molecular Oncology Diagnostics Market, Dynamics
Figure 4: Share of Key Market Strategies and Developments, January 2019-October 2022
Figure 5: Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021 Vs. 2032
Figure 6: Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021 Vs. 2032
Figure 7: Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021 Vs. 2032
Figure 8: Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021 Vs. 2032
Figure 9: Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021 Vs. 2032
Figure 10: Global Molecular Diagnostics Market (by Region), $Million, 2021 Vs. 2032
Figure 11: Role of Diagnostics in Healthcare
Figure 12: Global Molecular Oncology Diagnostics Market Segments
Figure 13: Global Molecular Oncology Diagnostics Market: Methodology
Figure 14: Primary Research Methodology
Figure 15: Bottom-Up Approach (Segment-Wise Analysis)
Figure 16: Top-Down Approach (Segment-Wise Analysis)
Figure 18: Solid Tumor Prevalence and Incidence Data in Europe, 2020
Figure 19: Hematological Malignancy Prevalence and Incidence Data in North America, 2020
Figure 20: Solid Tumor Prevalence and Incidence Data in Europe, 2020
Figure 21: Hematological Malignancy Prevalence and Incidence Data in Europe, 2020
Figure 22: Solid Tumor Prevalence and Incidence Data in Asia-Pacific, 2020
Figure 23: Hematological Malignancy Prevalence and Incidence Data in Asia-Pacific, 2020
Figure 25: Prominent FDA-Approved CDx Tests for Molecular Oncology Diagnostics
Figure 26: FDA Guidelines for CDx Approval
Figure 27: Criteria for CMS Coverage/Reimbursement
Figure 28: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
Figure 29: Workflow for Medical Device Regulations
Figure 30: Global Molecular Diagnostics Market: Market Dynamics
Figure 31: Likert Scale

14
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Figure 32: Impact Analysis of Market Drivers and Challenges on the Global Molecular Oncology
Diagnostics Market
Figure 33: Global Distribution of Cases and Deaths (by Cancer Type), 2020
Figure 34: Global Incidence for Cancer Types (2017-2019)
Figure 35: Product Upgradations and Technological Advancements, 2019-2022
Figure 36: Synergistic Activities, 2019-2021
Figure 37: Share of Key Developments and Strategies, January 2019-October 2022
Figure 38: Share of Mergers and Acquisitions (by Company), January 2019-October 2022
Figure 39: Share of Synergistic Activities (by Company), January 2019-October 2022
Figure 40: Share of Product Launch and Approval Activities (by Company), January 2019-October 2022
Figure 41: Share of Expansion, Insurance, and Other Key Developments (by Company), January 2019-
October 2022
Figure 42: Market-Share Analysis for the Global Molecular Oncology Diagnostics Market, $Million, 2021
Figure 43: Growth-Share Analysis of Global Molecular Oncology Diagnostics Market (by Technology),
2021-2032
Figure 44: Global Molecular Oncology Diagnostics Market (by Product)
Figure 45: Share of Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021 and 2032
Figure 46: Global Molecular Oncology Diagnostics Market (Kits and Assays), $Million, 2021-2032
Figure 47: Global Molecular Oncology Diagnostics Market (Instruments), $Million, 2021-2032
Figure 48: Global Molecular Oncology Diagnostics Market (Software), $Million, 2021-2032
Figure 49: Global Molecular Oncology Diagnostics Market (by Technology)
Figure 50: Share of Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021 and
2032
Figure 51: Global Molecular Oncology Diagnostics Market (Polymerase Chain Reaction), $Million, 2021-
2032
Figure 52: Global Molecular Oncology Diagnostics Market (Next-Generation Sequencing), $Million, 2021-
2032
Figure 53: Global Molecular Oncology Diagnostics Market (Immunohistochemistry), $Million, 2021-2032
Figure 54: Global Molecular Oncology Diagnostics Market (Fluorescence In-Situ Hybridization), $Million,
2021-2032
Figure 55: Global Molecular Oncology Diagnostics Market (Flow Cytometry), $Million, 2021-2032
Figure 56: Global Molecular Oncology Diagnostics Market (Other Technologies), $Million, 2021-2032
Figure 57: Share of Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021 and
2032

15
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Figure 58: Global Molecular Oncology Diagnostics Market (Clinical Diagnostic), $Million, 2021-2032
Figure 59: Global Molecular Oncology Diagnostics Market (Research Use), $Million, 2021-2032
Figure 60: Global Molecular Oncology Diagnostics Market (by Cancer Type)
Figure 61: Share of Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021 and
2032
Figure 62: Global Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021 and 2032
Figure 63: Global Molecular Oncology Diagnostics Market (Breast Cancer), $Million, 2021-2032
Figure 64: Global Molecular Oncology Diagnostics Market (Lung Cancer), $Million, 2021-2032
Figure 65: Global Molecular Oncology Diagnostics Market (Colorectal Cancer), $Million, 2021-2032
Figure 66: Global Molecular Oncology Diagnostics Market (Prostate Cancer), $Million, 2021-2032
Figure 67: Global Molecular Oncology Diagnostics Market (Ovarian Cancer), $Million, 2021-2032
Figure 68: Global Molecular Oncology Diagnostics Market (Other Solid Tumors), $Million, 2021-2032
Figure 69: Global Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021
and 2032
Figure 70: Global Molecular Oncology Diagnostics Market (Lymphoma), $Million, 2021-2032
Figure 71: Global Molecular Oncology Diagnostics Market (Leukemia), $Million, 2021-2032
Figure 72: Global Molecular Oncology Diagnostics Market (Multiple Myeloma), $Million, 2021-2032
Figure 73: Global Molecular Oncology Diagnostics Market (Other Hematological Malignancies), $Million,
2021-2032
Figure 74: Share of Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021 and
2032
Figure 75: Global Molecular Oncology Diagnostics Market (Hospitals and Diagnostic Centers), $Million,
2021-2032
Figure 76: Global Molecular Oncology Diagnostics Market (Reference Laboratories), $Million, 2021-2032
Figure 77: Global Molecular Oncology Diagnostics Market (Pharmaceutical and Biotechnology
Companies), $Million, 2021-2032
Figure 78: Global Molecular Oncology Diagnostics Market (Academic and Research Institutes), $Million,
2021-2032
Figure 79: Global Molecular Oncology Diagnostics Market Snapshot (by Region), $Million, 2021-2032
Figure 80: Global Molecular Oncology Diagnostics Market (by Region), $Million, 2021-2032
Figure 81: North America Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 82: North America: Market Dynamics
Figure 83: North America Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032
Figure 84: U.S. Molecular Oncology Diagnostics Market, $Million, 2021-2032

16
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Figure 85: U.S. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 86: U.S. Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 87: U.S. Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-
2032
Figure 88: Canada Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 89: Canada Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 90: Canada Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 91: Canada Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million,
2021-2032
Figure 92: Europe Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 93: Europe: Market Dynamics
Figure 94: Europe Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032
Figure 95: Germany Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 96: Germany Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 97: Germany Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 98: Germany Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million,
2021-2032
Figure 99: France Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 100: France Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 101: France Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 102: France Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-
2032
Figure 103: U.K. Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 104: U.K. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 105: U.K. Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 106: U.K. Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-
2032
Figure 107: Italy Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 108: Italy Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 109: Italy Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 110: Italy Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-
2032
Figure 111: Spain Molecular Oncology Diagnostics Market, $Million, 2021-2032

17
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Figure 112: Spain Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 113: Spain Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 114: Spain Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-
2032
Figure 115: Rest-of-Europe Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 116: Rest-of-Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 117: Rest-of-Europe Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 118: Rest-of-Europe Molecular Oncology Diagnostics Market (by Hematological Malignancy),
$Million, 2021-2032
Figure 119: Asia-Pacific Molecular Oncology Diagnostics Market (by Region), $Million, 2021-2032
Figure 120: Asia-Pacific: Market Dynamics
Figure 121: Asia-Pacific Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032
Figure 122: China Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 123: China Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 124: China Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 125: China Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-
2032
Figure 126: India Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 127: India Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 128: India Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 129: India Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-
2032
Figure 130: Japan Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 131: Japan Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 132: Japan Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 133: Japan Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-
2032
Figure 134: South Korea Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 135: South Korea Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 136: South Korea Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 137: South Korea Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million,
2021-2032
Figure 138: Australia Molecular Oncology Diagnostics Market, $Million, 2021-2032

18
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Figure 139: Australia Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032
Figure 140: Australia Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032
Figure 141: Australia Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million,
2021-2032
Figure 142: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 143: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-
2032
Figure 144: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-
2032
Figure 145: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Hematological Malignancy),
$Million, 2021-2032
Figure 146: Rest-of-the-World Molecular Oncology Diagnostics Market, $Million, 2021-2032
Figure 147: Total Number of Companies Profiled
Figure 148: Agilent Technologies, Inc.: Product Portfolio
Figure 149: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
Figure 150: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 151: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 152: Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021
Figure 153: Abbott.: Overall Product Portfolio
Figure 154: Abbott.: Overall Financials, $Million, 2019-2021
Figure 155: Abbott.: Revenue (by Segment), $Million, 2019-2021
Figure 156: Abbott.: Revenue (by Region), $Million, 2019-2021
Figure 157: Abbott.: R&D Expenditure, $Million, 2019-2021
Figure 158: Biocartis NV.: Product Portfolio
Figure 159: Biocartis NV: Overall Financials, $Million, 2019-2021
Figure 160: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 161: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 162: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 163: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 164: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 165: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 166: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2019-2021
Figure 167: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2019-2021

19
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Figure 168: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2019-2021
Figure 169: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 170: QIAGEN N.V.: Product Portfolio
Figure 171: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 172: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 173: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
Figure 174: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 175: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 176: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2019-2021
Figure 177: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 178: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 179: Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 180: Danaher.: Product Portfolio
Figure 181: Danaher.: Overall Financials, $Million, 2019-2021
Figure 182: Danaher.: Revenue (by Segment), $Million, 2019-2021
Figure 183: Danaher.: Revenue (by Region), $Million, 2019-2021
Figure 184: Danaher.: R&D Expenditure, $Million, 2019-2021
Figure 185: Guardant Health: Overall Product Portfolio
Figure 186: Guardant Health: Overall Financials, $Million, 2019-2021
Figure 187: Guardant Health: Revenue (by Segment), 2019-2021
Figure 188: Guardant Health: R&D Expenditure, $Million, 2019-2021
Figure 189: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
Figure 190: HTG Molecular Diagnostics, Inc.: Overall Financials, $Million, 2019-2021
Figure 191: HTG Molecular Diagnostics, Inc.: Revenue (by Segment), 2019-2021
Figure 192: HTG Molecular Diagnostics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 193: Illumina, Inc.: Overall Product Portfolio
Figure 194: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 195: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 196: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 197: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 198: Invivoscribe, Inc.: Overall Product Portfolio
Figure 199: Myriad Genetics, Inc.: Product Portfolio
Figure 200: Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021

20
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Figure 201: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 202: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 203: Sysmex Corporation: Overall Product Portfolio
Figure 204: Sysmex Corporation: Overall Financials, $Million, 2019-2021
Figure 205: Sysmex Corporation: Revenue (by Region), $Million, 2019-2021
Figure 206: Sysmex Corporation: R&D Expenditure, $Million, 2019-2021

21
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
List of Tables
Table 1: Biomarkers for Different Cancer Types
Table 2: Cost of Liquid Biopsy Based NGS Diagnostic Kits
Table 3: Companies Providing Kits and Assays for Molecular Oncology Diagnostics

22
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

23
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

24
G
L
O
B
A
L
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
D
I
A
G
N
O
S
T
I
C
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032

Recommended

Recommended

More Related Content

Similar to Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032

Similar to Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032 (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032